文献速递肿瘤 PET/CT

18F-Fluciclovine PET/CT检测根治术后PSA≤1 ng/mL的复发性前列腺癌

18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该回顾性研究纳入28例根治性治疗后疑似复发且血清PSA≤1 ng/mL的前列腺癌患者,用18F-Fluciclovine PET/CT寻找复发灶。13例(46.4%)检出至少一处复发灶,Gleason评分>7者检出率显著更高(P=0.004),而PSA均值与PSA倍增时间在阳性与阴性扫描间无显著差异。

要点

  • PSA≤1 ng/mL的疑似复发患者中,18F-Fluciclovine PET/CT检出复发灶比例为46.4%。
  • Gleason评分>7的患者扫描阳性率显著更高(P=0.004)。
  • 阳性与阴性扫描患者的PSA均值及PSA倍增时间无显著差异。

核心结论

  • 18F-Fluciclovine PET/CT可在PSA≤1 ng/mL的低水平升高患者中检出前列腺癌复发。
  • 此类患者以局部和淋巴结复发较远处转移更常见,Gleason评分>7与扫描阳性相关。

研究设计与样本

  • 回顾性研究,纳入28例根治性治疗后疑似复发且血清PSA≤1 ng/mL的前列腺癌男性患者。
  • 采用18F-Fluciclovine PET/CT识别复发部位,并用Fisher精确检验和独立两组t检验比较组间差异。

主要发现

  • 28例中13例(46.4%)检出至少一处复发灶。
  • Gleason评分>7患者疾病检出率显著更高(Fisher精确检验,P=0.004)。
  • 阳性与阴性扫描患者的平均PSA及平均PSA倍增时间无显著差异(P=0.29和P=0.70)。

临床怎么用

  • 对根治性治疗后PSA≤1 ng/mL且疑似复发的前列腺癌患者,可考虑18F-Fluciclovine PET/CT定位复发灶。
  • Gleason评分>7的患者扫描阳性可能性更高,解读结果时可结合该病史。

局限性

  • 回顾性研究,样本量仅28例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of this study were to report on our initial experience using F-fluciclovine PET/CT to detect recurrent prostate carcinoma in patients with low serum prostate-specific antigen (PSA) after definitive treatment of primary disease and to conduct a preliminary investigation for factors associated with positive scan findings. PATIENTS AND METHODS: In this retrospective study, F-fluciclovine PET/CT scans from 28 men with suspected recurrence of prostate carcinoma and PSA values of 1 ng/mL or less were examined to identify the site(s) of disease recurrence. Differences in detection rate for Gleason scores of 7 and greater than 7, T2 and T3 disease, negative and positive surgical margins, and negative and positive seminal vesicle invasion were compared using the Fisher exact test. Mean PSA and mean PSA doubling time of patients with positive scans and negative scans were compared using the independent 2-group t test. RESULTS: At least one site of disease recurrence was identified in 13 (46.4%) of 28 patients. Disease detection rate was significantly higher in patients with history of Gleason score greater than 7 (Fisher exact test, P = 0.004). Mean PSA and PSA doubling time were not significantly different between patients with positive and negative F-fluciclovine PET/CT scans (P = 0.29 and 0.70, respectively). CONCLUSIONS: Detection of recurrent prostate cancer using F-fluciclovine PET/CT is possible in patients with low but rising PSA levels of 1 ng/mL or less. In such patients, local and nodal recurrences are more common than distant metastasis, and Gleason score greater than 7 is associated with positive scan results.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. England JR, Paluch J, Ballas LK, et al. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment. Clin Nucl Med. 2019. PMID: 30589673. doi:10.1097/RLU.0000000000002432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。